CRISPR-based Gene Editing Market Report 2025, with Company Profiles of the Top 10+ Major Market Players
The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added ...
CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers
CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...
China-born gene-editing star scientist Zhang Feng recognised with top US prize
CRISPR-Cas9 pioneer presented with National Medal of Technology and Innovation in White House awards ceremony.
ERS Genomics launches ‘Express License’ platform to democratise access to CRISPR/Cas9
The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...
Putting the gene editing tool to use
Gene editing involves precise changes in DNA sequences using enzymes, revolutionizing medical, agricultural, and research ...
Scientists engineer CRISPR enzymes that evade immune system
The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...
EurekAlert!3d
Integrating CRISPR and biomaterials engineering: Paving the way for safer gene therapies
Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones
Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...
Morningstar3d
ERS Genomics launches ‘Express License’ platform to democratise access to CRISPR/Cas9
The new Express License service removes barriers to accessing this transformative gene ... editing technology for startups. An Express License provides fast, simple and affordable access to the ...
2 bold stock market ideas to consider for a Stocks and Shares ISA
Our writer thinks these two speculative shares offer high long-term growth potential from where they currently sit in the ...
Editas Medicine Outlines 2025 Strategic Priorities and Milestones
Editas Medicine ( (EDIT) ) has provided an announcement. Editas Medicine announced new in vivo preclinical proof of concept data and outlined its strategic priorities and key milestones for 2025, ...